These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12270383)

  • 1. FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients.
    Boehler T; Schuetz M; Budde K; Neumayer H; Waiser J
    Transplant Proc; 2002 Sep; 34(6):2242-3. PubMed ID: 12270383
    [No Abstract]   [Full Text] [Related]  

  • 2. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.
    Böhler T; Waiser J; Schuetz M; Neumayer HH; Budde K
    Nephrol Dial Transplant; 2004 Mar; 19(3):702-13. PubMed ID: 14767029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue effect of FTY720 on acute renal rejection in dogs.
    Yuzawa K; Otsuka M; Taniguchi H; Takada Y; Sakurayama N; Jinzenji Y; Suzuki S; Fukao K
    Transplant Proc; 1999; 31(1-2):872. PubMed ID: 10083381
    [No Abstract]   [Full Text] [Related]  

  • 4. Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model.
    Suzuki T; Shimamura T; Jin MB; Yokota R; Fukai M; Iida J; Taniguchi M; Magata S; Horiuchi H; Yamashita K; Nomura M; Omura T; Kishida A; Furukawa H; Todo S
    Transplant Proc; 1999; 31(1-2):1208-9. PubMed ID: 10083540
    [No Abstract]   [Full Text] [Related]  

  • 5. FTY720 and central memory: out of sight, out of mind.
    Slavin AJ; Zamvil SS
    Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
    [No Abstract]   [Full Text] [Related]  

  • 6. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.
    Budde K; Schmouder RL; Brunkhorst R; Nashan B; Lücker PW; Mayer T; Choudhury S; Skerjanec A; Kraus G; Neumayer HH
    J Am Soc Nephrol; 2002 Apr; 13(4):1073-1083. PubMed ID: 11912269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effect of FTY720 on acute rejection in canine renal transplantation.
    Yuzawa K; Otsuka M; Taniguchi H; Takada Y; Sakurayama N; Jinzenji Y; Suzuki S; Fukao K
    Transplant Proc; 1998 Jun; 30(4):1046. PubMed ID: 9636422
    [No Abstract]   [Full Text] [Related]  

  • 8. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
    Hofmann M; Brinkmann V; Zerwes HG
    Int Immunopharmacol; 2006 Dec; 6(13-14):1902-10. PubMed ID: 17161343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
    Park SI; Felipe CR; Machado PG; Garcia R; Skerjanec A; Schmouder R; Tedesco-Silva H; Medina-Pestana JO
    Braz J Med Biol Res; 2005 May; 38(5):683-94. PubMed ID: 15917949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism.
    Böhler T; Waiser J; Schütz M; Friedrich M; Schötschel R; Reinhold S; Schmouder R; Budde K; Neumayer HH
    Transpl Int; 2000; 13 Suppl 1():S311-3. PubMed ID: 11112021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing.
    Yanagawa Y; Masubuchi Y; Chiba K
    Immunology; 1998 Dec; 95(4):591-4. PubMed ID: 9893050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes.
    Böhler T; Waiser J; Schütz M; Dragun D; Neumayer HH; Budde K
    Transplantation; 2004 May; 77(9):1424-32. PubMed ID: 15167602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD.
    Schuurman HJ; Menninger K; Audet M; Kunkler A; Maurer C; Vedrine C; Bernhard M; Gaschen L; Brinkmann V; Quesniaux V
    Transplantation; 2002 Oct; 74(7):951-60. PubMed ID: 12394836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
    Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L
    Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A short-course therapy with FTY720 prolongs allograft survival after canine kidney transplantation.
    Omura T; Suzuki T; Shimamura T; Jin MB; Yokota R; Fukai M; Iida J; Taniguchi M; Magata S; Horiuchi H; Yamashita K; Nomura M; Kishida A; Matsushita M; Furukawa H; Todo S
    Transplant Proc; 1999 Nov; 31(7):2783-4. PubMed ID: 10578289
    [No Abstract]   [Full Text] [Related]  

  • 16. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation.
    Brinkmann V; Pinschewer D; Chiba K; Feng L
    Trends Pharmacol Sci; 2000 Feb; 21(2):49-52. PubMed ID: 10664606
    [No Abstract]   [Full Text] [Related]  

  • 17. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons.
    Quesniaux V; Fullard L; Arendse H; Davison G; Markgraaff N; Auer R; Ehrhart F; Kraus G; Schuurman HJ
    Transpl Immunol; 1999 Sep; 7(3):149-57. PubMed ID: 10608298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
    Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
    Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts.
    Yanagawa Y; Hoshino Y; Kataoka H; Kawaguchi T; Ohtsuki M; Sugahara K; Chiba K
    Transplant Proc; 1999; 31(1-2):1227-9. PubMed ID: 10083548
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients.
    Böhler T; Schütz M; Budde K; Neumayer HH; Waiser J
    Int Immunopharmacol; 2007 Jan; 7(1):88-95. PubMed ID: 17161821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.